ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more…
The company received support of more than $1bn from the US Biomedical Advanced Research and Development Authority (BARDA) Broad and…
CAMBRIDGE, 07-Aug-2017 — /EuropaWire/ — AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the…